The prevalence of hepatitis B virus (HBV), hepatitis C virus (HCV), an
d their associations in 405 hemodialysis (HD) patients (209 males and
196 females) was evaluated in this study. A comparison was also made w
ith 526 normal patients (266 males and 260 females). Screening for hep
atitis B antibody was carried out with the radioimmunoassay (RIA) meth
od, and for anti-HCV with the enzyme immunoassay (EIA) method. Three h
undred and thirty-two HD patients (82.0%) were anti-HBc positive, with
no significant difference from the control group (81.9%). One hundred
and forty-five HD patients (35.8%) were anti-HCV positive, a much gre
ater prevalance than the control group (4.9%). The high prevalence of
HBV in these HD patients probably reflects acquisition of HBV infectio
n before entry onto chronic dialytic therapy in a region of the world
that is hyper-endemic for HBV. On the contrary, the prevalence of sero
positivity to anti-HCV correlated with the number of transfusions, the
length of time on HD, and a higher rate of dialyzer reuse. Similar co
rrelations occurred in those HD patients with seropositivity to both a
nti-HBc and anti-HCV. A higher prevalence rate of HCV infection in our
study was observed when compared with other countries (35.8% vs. 7-23
%), even though our patients had a relatively shorter mean duration of
HD (40 months vs. 57-66 months). We conclude that blood transfusions,
dialyzer reuse, and patient-to-patient contamination during HD play a
role in the higher prevalence rate of HCV infection, as well as in co
mbined HBV and HCV infections, in HD patients.